Anja Harmeier has been appointed to lead Roche's startup investment division following the retirement of Carole Nuechterlein. Harmeier, who previously worked with Roche Venture Fund from 2016 to 2020, brings extensive experience from her role as CEO at Rewind Therapeutics, where she worked for over four years.
In addition to her time at Roche, Harmeier was a partner at BB Pureos Bioventures for 18 months. She expressed gratitude toward Nuechterlein, acknowledging her mentorship in venture capital. Roche Venture Fund, with a total of CHF 750 million (approximately $940 million), is dedicated to investing in startups within pharmaceuticals, diagnostics, and digital health.
Recent investments from the fund include companies like Mission Therapeutics, SpliceBio, and GlycoEra, which focus on advancing treatments in mitochondrial diseases, gene therapy, and precision immunology, respectively.